Fortress Biotech, Inc. (FBIO)

Fortress Biotech, Inc.'s stock price has experienced significant movement in the past six months, increasing by 54.17% from November 25, 2024, to November 21, 2025, and delivering a 77.03% change over the past year. Recent events impacting the stock include a 13% surge in the stock price around September 23, 2025, the announcement of its third-quarter 2025 financial results on November 12, 2025, and Avenue Therapeutics' acquisition by Axsome Therapeutics on November 5, 2025. In May 2024, the FDA accepted the NDA filing for DFD-29, with a PDUFA goal date of November 4, 2024.

Information regarding the specific demand seasonality for Fortress Biotech, Inc.'s products and services is not explicitly detailed in the provided search results. Therefore, specific demand seasonality for FBIO products and services cannot be provided.

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products within the Health Care sector. Their business model includes in-house development and partnerships to expand their product portfolio. The company's product portfolio includes marketed dermatology products like Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Fortress Biotech has a pipeline of development-stage candidates across various therapeutic areas, including oncology, rare diseases, and gene therapy.

Fortress Biotech, Inc. is headquartered in Bay Harbor Islands, Florida, United States, and its stock is traded on the Nasdaq exchange under the ticker symbol FBIO. The company's strategy involves acquiring and advancing assets, including licensing worldwide rights for certain drug candidates, suggesting a potential global reach for its products and development programs through partnerships.

Fortress Biotech's brand reputation, as reflected by analyst sentiment, generally indicates a "Hold" consensus rating, with two analysts giving a "Strong Buy" consensus rating as of November 27, 2025. The company is perceived to have a "Moderate risk with adequate balance sheet." Positive developments, such as the FDA's acceptance of the NDA for DFD-29 and projected revenue growth in its Dermatology segment, contribute positively to its reputation.

Fortress Biotech, Inc. has a diverse ownership structure comprising institutional, retail, and individual investors. Institutional investors hold approximately 5.36% to 18.12% of the company's stock, with major shareholders including Vanguard Group Inc and Blackrock, Inc. Individual investors hold a significant portion of the company's stock, estimated to be between 58% and 83.93%, with David Jin owning the most shares. Insider ownership is approximately 4.20% to 29.75%.